Silence Therapeutics plc (NASDAQ: SLN) closed an underwritten public offering of 14,907,407 American Depositary Shares (ADSs) at $13.50 per ADS, according to a press release statement.

The total includes the full exercise by underwriters of their option to purchase an additional 1,944,444 ADSs. Gross proceeds from the offering reached approximately $201.3 million, before deducting underwriting discounts, commissions, and other offering expenses.

Each ADS represents three ordinary shares of £0.05 each in the capital of the company. Jefferies, Morgan Stanley, Cantor, and William Blair acted as joint book-running managers for the offering.

A shelf registration statement related to the offering was filed with the U.S. Securities and Exchange Commission on May 18, 2026, and declared effective on May 27, 2026.